Multicentre international study capecitabine +/- bevacizumab as adjuvant treatment of colorectal cancer.

Trial Profile

Multicentre international study capecitabine +/- bevacizumab as adjuvant treatment of colorectal cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Capecitabine (Primary) ; Bevacizumab
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms QUASAR-2
  • Sponsors Roche
  • Most Recent Events

    • 19 Sep 2016 Primary endpoint (Disease free survival rate at 3 years ) has not been met,according to the results published in the Lancet Oncology
    • 19 Sep 2016 Results assessing disease free survival published in the Lancet Oncology (2016).
    • 29 Oct 2013 Accrual to date is 100% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top